Fidelis Capital Partners LLC Sells 10,146 Shares of Novo Nordisk A/S (NYSE:NVO)

Fidelis Capital Partners LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,183 shares of the company's stock after selling 10,146 shares during the period. Fidelis Capital Partners LLC's holdings in Novo Nordisk A/S were worth $290,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of NVO. Strategic Investment Solutions Inc. IL increased its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $33,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Trading Down 2.9%

Shares of NVO traded down $2.08 during trading hours on Friday, hitting $68.93. 6,511,310 shares of the stock traded hands, compared to its average volume of 7,333,909. The business has a fifty day moving average of $70.35 and a 200-day moving average of $75.00. The firm has a market capitalization of $307.77 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 1.34 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.